Quantcast

Latest Hydrocodone Stories

2014-09-08 08:30:58

Studies to Investigate Ability of KP201 to Deter Abuse and Reduce Opioid-Induced Constipation CORALVILLE, Iowa, Sept. 8, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the initiation of clinical trials of KP201 designed to investigate the drug candidate's ability to deter abuse and reduce opioid-induced constipation. KP201 (benzhydrocodone hydrochloride...

2014-09-04 16:27:27

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential in recreational opioid abusers at PAINWeek national conference Sept. 2 - 6 in Las Vegas....

2014-08-29 23:06:02

DEA’s announcement comes after a recommendation last year concerning the potent combination drug products. Port Washington, New York (PRWEB) August 29, 2014 Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications reports that the Drug Enforcement Administration (DEA) has announced new regulations for all hydrocodone combination products. According to a Regulatory Affairs Professionals Society (RAPS)...

2014-08-28 23:17:30

Controversial Hydrocodone-Based Painkiller Zohydro contains strong potential for addiction and as a substitute for OxyContin and heroin abuse. Aid in Recovery calls for the removal of the drug from the market. (PRWEB) August 28, 2014 Aid in Recovery, a full service drug and alcohol treatment center, released a statement today regarding the potential for abuse of a dangerous new painkiller, Zohydro, which is marketed to chronic pain sufferers. The drug, an extended-release painkiller that...

Bioengineers Close To Creating Painkillers Without Using Opium From Poppies
2014-08-27 03:56:55

By Tom Abate, Stanford School of Engineering A decade-long effort in genetic engineering is close to creating yeast that makes palliative medicines in stainless steel vats. For centuries poppy plants have been grown to provide opium, the compound from which morphine and other important medicines such as oxycodone are derived. Now bioengineers at Stanford have hacked the DNA of yeast, reprograming these simple cells to make opioid-based medicines via a sophisticated extension of the...

2014-08-06 20:23:58

Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States TOKYO, PARSIPPANY, N.J. and JUPITER, Fla., Aug. 6, 2014 /PRNewswire/ -- Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have entered into a strategic collaboration for the development and U.S....

2014-07-31 23:14:43

CR urges U.S. Food and Drug Administration to take stronger steps to reduce the dangers of pain-relief medications YONKERS, NY (PRWEB) July 31, 2014 Some pain relief medications can be as addictive as heroin and are rife with deadly side effects. Every day, 46 people in the U.S. die from legal pain pills and for each death, more than 30 people are admitted to an emergency room because of opioid complications. Consumer Reports has taken a close look at the dangers of prescription and...

2014-07-29 08:34:16

WAYNE, Pa., July 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Egalet's website. Please...

2014-07-08 08:31:18

Anticipated FDA action set for October 2014 STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.